Novo Nordisk A/S (NYSE:NVO) Receives Consensus Rating of “Hold” from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO) have been assigned a consensus recommendation of “Hold” from the twenty-three brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, seventeen have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $53.9286.

Several research firms recently issued reports on NVO. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised Novo Nordisk to Equal Weight, and related analyst chatter lifted the stock in earlier trading — a near-term supportive catalyst. Novo Nordisk A/S (NYSE:NVO) Raised to Equal Weight at Morgan Stanley
• Neutral Sentiment: General coverage and “trending” write-ups (Zacks/Yahoo) are driving retail attention but contain no new fundamental news; these pieces can increase volume/volatility without changing long‑term fundamentals. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Be aware of ticker-noise: several press releases referencing “NVO” (Novo Resources, ASX: NVO) circulated today — these are not related to Novo Nordisk (NYSE:NVO) but can create confusion in scanners and newsfeeds. Completion of Tranche 1 of Placement and Valuation Update
• Negative Sentiment: Roche reported positive Phase II results for petrelintide (up to ~10.7% weight loss with good tolerability) and plans further development — new obesity competitors gaining efficacy/tolerability could pressure Novo Nordisk’s market share and growth expectations. Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
• Negative Sentiment: A study reporting generic Ozempic/Wegovy could be produced for under $3/month highlights potential long‑term pricing pressure and margin risk if cheaper biosimilars/generics scale globally. That raises erosion risk to high-margin GLP‑1 revenues. Generic Ozempic Could Cost Less Than $3 a Month, Study Shows
• Negative Sentiment: Regulatory scrutiny increased after the FDA issued (another) warning about marketing/ads for Ozempic/Wegovy — ongoing ad/regulatory issues could hurt promotion and patient uptake and lead to fines or stricter controls. FDA sends Novo Nordisk 2nd warning over GLP-1 ads
• Negative Sentiment: Pomerantz law firm announced an investigation into Novo Nordisk investor claims, which can increase legal uncertainty and weigh on sentiment until resolved. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors have recently modified their holdings of NVO. Union Savings Bank acquired a new position in Novo Nordisk A/S during the 4th quarter worth $312,000. Mengis Capital Management Inc. raised its position in Novo Nordisk A/S by 303.2% in the 4th quarter. Mengis Capital Management Inc. now owns 66,694 shares of the company’s stock valued at $3,393,000 after purchasing an additional 50,154 shares in the last quarter. AG Campbell Advisory LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at about $122,000. Rehmann Capital Advisory Group boosted its stake in shares of Novo Nordisk A/S by 33.6% in the 4th quarter. Rehmann Capital Advisory Group now owns 18,552 shares of the company’s stock valued at $944,000 after buying an additional 4,664 shares during the period. Finally, SHP Wealth Management purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $67,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $38.60 on Monday. Novo Nordisk A/S has a fifty-two week low of $35.85 and a fifty-two week high of $88.55. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The company has a 50 day moving average price of $51.41 and a 200 day moving average price of $52.35. The stock has a market capitalization of $172.35 billion, a P/E ratio of 11.12 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 52.74%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.